<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646358</url>
  </required_header>
  <id_info>
    <org_study_id>MST-188-10</org_study_id>
    <nct_id>NCT02646358</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer</brief_title>
  <official_title>A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study designed to evaluate the effect of renal disease on the
      pharmacokinetics of vepoloxamer relative to the pharmacokinetics in healthy subjects with
      normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics variable - Area under the plasma concentration curve</measure>
    <time_frame>Time zero through 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v.4.03</measure>
    <time_frame>Time zero through Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Pharmacokinetics of Vepoloxamer</condition>
  <condition>Healthy Volunteers</condition>
  <condition>Renal Impaired</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: End Stage Renal Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vepoloxamer</intervention_name>
    <arm_group_label>Cohort 1: Normal Renal Function</arm_group_label>
    <arm_group_label>Cohort 2: Mild Renal Impairment</arm_group_label>
    <arm_group_label>Cohort 3: Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Cohort 4: Severe Renal Impairment</arm_group_label>
    <arm_group_label>Cohort 5: End Stage Renal Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subject must weigh â‰¤ 125 kg and have a body mass index between 20 and 40 kg/m2

          -  Subject must be willing to be confined in the clinical research unit for the duration
             of the study, up to 5 days

          -  If female, subject must not be pregnant or lactating, have a negative pregnancy test,
             and agrees to sexual abstinence, or use of an appropriate birth control method from
             screening through 30 days after study drug administration

          -  If male, subject agrees to sexual abstinence, is surgically sterile, or is using an
             appropriate birth control method from screening through 30 days after study drug
             administration

          -  Considered by the Investigator to be healthy or clinically stable with respect to
             underlying renal impairment based on medical evaluation including vital signs, ECG and
             laboratory test results

          -  Non-smoker, or smokes fewer than 10 cigarettes/day

        Key Exclusion Criteria

          -  Uncontrolled medical condition (treated or untreated) considered to be clinically
             significant by the Investigator

          -  Experienced an illness considered by the Investigator to be clinically significant
             within 2 weeks of study drug administration

          -  Treatment with another investigational drug or device study within 30 days or 5
             half-lives (whichever is longer) prior to screening

          -  Positive test for drugs of abuse and/or positive alcohol test at Screening or Day -1

          -  Donated or lost a significant volume of blood or plasma within 90 days prior to study
             drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin L Parsley, DO</last_name>
    <role>Study Director</role>
    <affiliation>Mast Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

